Hypoactive Sexual Desire Disorder (HSDD)

Vyleesi Fact Sheet

By Evita Almassi | Jul 12, 2019 | Comments Off on Vyleesi Fact Sheet

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

Addyi Health Fact Sheet

By NWHN Staff | Jul 30, 2018 | Comments Off on Addyi Health Fact Sheet

Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.

How Can I Get an Addyi Prescription if My Insurance Does Not Cover It?

By NWHN Staff | Jun 28, 2018 | Comments Off on How Can I Get an Addyi Prescription if My Insurance Does Not Cover It?

“My doctor prescribed me Addyi for HSDD. I cannot afford it and my insurance does not cover it. Are there any other resources to get this medication?”

Flibanserin Update: Health and Safety Concerns Continue to Be Profound

By NWHN Staff | Mar 2, 2016 | Comments Off on Flibanserin Update: Health and Safety Concerns Continue to Be Profound

Rather than a failed “fix-all” pill, NWHN encourages rigorous research be conducted exploring the causes of women’s sexual problems, possible solutions, and what, if anything, might constitute “normal” when it comes to women’s sexuality.

Consumer Alert — Pass on the Pink Pill or Pass Out

By NWHN Staff | Nov 12, 2015 | Comments Off on Consumer Alert — Pass on the Pink Pill or Pass Out

The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.

Flibanserin: The FDA’s Approval Is Bad Science and a Bad Precedent

By NWHN Staff | Nov 10, 2015 | Comments Off on Flibanserin: The FDA’s Approval Is Bad Science and a Bad Precedent

This year, the Food and Drug Administration (FDA) made history — for all the wrong reasons.

The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

By NWHN Staff | Oct 16, 2015 | Comments Off on The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640

Top 10 Things to Know About Today’s Sex Drive Drugs

By NWHN Staff | Oct 15, 2015 | Comments Off on Top 10 Things to Know About Today’s Sex Drive Drugs

Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.

National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex Drug

By Cindy Pearson | Jun 3, 2015 | Comments Off on National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex Drug

FOR IMMEDIATE RELEASE 
Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788

FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

By Cindy Pearson | Oct 28, 2014 | Comments Off on FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder